financetom
Business
financetom
/
Business
/
Loeb's Third Point rises 8% in Q1, driven by activist strategy - source
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Loeb's Third Point rises 8% in Q1, driven by activist strategy - source
Apr 1, 2024 9:33 AM

NEW YORK, April 1 (Reuters) -

Billionaire investor Daniel Loeb's hedge fund Third Point

ended the first quarter with its main fund Offshore up 8%, while

the Ultra fund rose 8.7%, keeping performance gains seen at the

end of last year going into 2024, a source familiar with the

matter said.

The funds' returns were mainly driven this year by equities,

the source added, but credit and venture capital strategies also

boosted results.

Third Point pursues a number of investment strategies

including activism where it sometimes pushes companies to make

changes to perform better.

Early 2024 numbers show an ongoing improvement in

performance after the fund suffered a 22% loss in 2022 and

gained 3.6% last year.

The top engine to gains this year included bets on

Advance Auto Parts ( AAP ) and Bath & Body Works ( BBWI ), both

companies where Loeb and his team pressed for changes and the

companies announced new board members.

Electricity and power generation company Vistra ( VST )

helped Third Point's performance too, as it concluded the

acquisition of a nuclear power generator.

Big tech firms Amazon.com ( AMZN ) and Meta Platforms ( META )

were also contributors.

For years, Third Point has been among the industry's

most closely watched hedge funds for indications of trends in

the industry.

Recently, Loeb's firm has made additional inroads into

credit, which is already part of its strategy. Third Point is

raising a

private credit fund

and has plans to launch a corporate credit fund this

summer, the source said.

Third Point's assets under management ended March at $11.5

billion, roughly $700 million less than a year earlier.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
American Resources' Subsidiary ReElement Develops Capabilities to Produce Ultra-High-Purity Germanium
American Resources' Subsidiary ReElement Develops Capabilities to Produce Ultra-High-Purity Germanium
Aug 11, 2025
08:15 AM EDT, 08/11/2025 (MT Newswires) -- American Resources ( AREC ) said Monday its subsidiary ReElement Technologies has developed commercial protocols to produce ultra-high-purity germanium from both recycled and ore-based feedstocks for commercial and defense applications. The company added that ReElement has achieved greater than 99.9% purity and designed its commercial process flows to meet the demand for germanium...
Paramount Acquires Exclusive UFC Media Rights for $7.7 Billion
Paramount Acquires Exclusive UFC Media Rights for $7.7 Billion
Aug 11, 2025
08:16 AM EDT, 08/11/2025 (MT Newswires) -- Paramount Skydance ( PSKY ) and TKO Group Holdings ( TKO ) said Monday they have reached a seven-year, $7.7 billion media rights agreement through which Paramount will become the exclusive broadcast home for all UFC events in the US starting in 2026. ...
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
IO Biotech's cancer vaccine shows improvement in late-stage study goal
IO Biotech's cancer vaccine shows improvement in late-stage study goal
Aug 11, 2025
Aug 11 (Reuters) - IO Biotech ( IOBT ) said on Monday its experimental cancer vaccine, in combination with Merck's ( MRK ) Keytruda, showed improvement in a late-stage study goal, but was not statistically significant. It was testing the vaccine in 407 patients with advanced skin cancer. The company said it plans to meet with the U.S. Food and...
Copyright 2023-2026 - www.financetom.com All Rights Reserved